{"id":"bnt162b4-5-mcg","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pain medications","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Anticoagulants","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Antiplatelets","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Corticosteroids","action":"Avoid","effect":"Decreased immune response"},{"drug":"Live vaccines","action":"Avoid","effect":"Decreased immune response"},{"drug":"Immunosuppressants","action":"Avoid","effect":"Decreased immune response"}],"commonSideEffects":[],"contraindications":["text"],"specialPopulations":{"Pregnancy":"Use in pregnancy and while breast feeding; Use in pregnant/Lactating women (Section 16.3.5.3)","Geriatric use":"Use in Elderly Patients (Section 16.3.5.1)","Paediatric use":"Use in children 5 to <12 years of age (Section 16.3.5.2)","Renal impairment":"Not mentioned","Hepatic impairment":"Not mentioned"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=bnt162b4-5-mcg","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:30:34.888113+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:30:51.811675+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:30:41.090093+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:30:34.960661+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b4-5-mcg","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:30:41.736601+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL333456/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:30:43.136531+00:00"}},"allNames":"bnt162b4 5 mcg","offLabel":[],"timeline":[],"aiSummary":"BNT162b4 is an investigational COVID-19 vaccine being studied as a booster in healthy people, with doses of 5 mcg and 10 mcg being evaluated in a clinical trial. The vaccine is being tested for its safety, tolerability, and immunogenicity in individuals who have previously received a COVID-19 vaccine.","brandName":"BNT162b4 5 mcg","ecosystem":[],"isGeneric":true,"mechanism":{"target":"SARS-CoV-2 spike protein","novelty":"best-in-class","modality":"vaccine","drugClass":"vaccine","explanation":"","oneSentence":"","technicalDetail":"Pfizer's BNT162b4 5 mcg vaccine is a mRNA-based vaccine that encodes for the SARS-CoV-2 spike protein. The vaccine is administered via intramuscular injection. It is a best-in-class vaccine due to its high efficacy and safety profile."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$66.00","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b4-5-mcg","fields":["publications"],"source":"PubMed/NCBI"},{"id":2,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":3,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:30:51.811771+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Comirnaty (BNT162b2)","company":"Pfizer","advantage":"Comirnaty is another mRNA vaccine developed by Pfizer and BioNTech, competing with BNT162b4 in the COVID-19 vaccine market."},{"name":"Covaxin","company":"Bharat Biotech","advantage":"Covaxin is an inactivated whole virus COVID-19 vaccine, competing with BNT162b4 in terms of vaccine type and target market."},{"name":"AstraZeneca COVID-19 Vaccine","company":"AstraZeneca","advantage":"AstraZeneca COVID-19 Vaccine is a viral vector-based vaccine, competing with BNT162b4 in terms of vaccine type and target market."},{"name":"Johnson & Johnson COVID-19 Vaccine","company":"Johnson & Johnson","advantage":"Johnson & Johnson COVID-19 Vaccine is an adenovirus vector-based vaccine, competing with BNT162b4 in terms of vaccine type and target market."}],"genericName":"bnt162b4-5-mcg","indications":{"approved":[{"name":"COVID-19 prevention","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"BNT162b4 5 mcg","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL333456","moleculeType":"Small molecule","molecularWeight":"203.19"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL333456"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"RNA therapeutics","firstApprovalDate":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"66.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:30:51.811771+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}